Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly's Shopping Spree Won't Stop With Dermira, CFO Shares Plans For More Deals In 2020

By Cory Renauer - Updated Jan 17, 2020 at 11:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Midwest's largest drugmaker isn't finished making mid-sized deals.

Merger & acquisition activity at the 2020 J.P. Morgan Healthcare Conference has been a little disappointing, but not for a lack of effort on the part of Eli Lilly (LLY 0.51%). The big pharma went beyond the call of duty by announcing the $1.1 billion acquisition of Dermira (DERM) last week, and more recently its CFO John Smiley told investors to expect more deals this year.

The midwest's largest pharmaceutical company hasn't shared any specific details, but it's clear the company will get even larger in 2020. Smiley told Reuters to look for a new deal announcement in each quarter this year in the $1 billion and $5 billion range.

Prescription pills and cash money.

Image source: Getty Images.

What's on Eli Lilly's wish list?

While there are plenty of young growth drivers in Lilly's product line, sales of aging insulin lispro products sold under the Humalog brand are under a lot of pressure. Instead of growing its presence in the increasingly crowded space for diabetes drugs, though, Eli Lilly will probably continue expanding into immunology and oncology.

The recent acquisition of Dermira gives Lilly access to an experimental treatment for eczema which could be an important revenue stream in the years ahead. Last year's purchase of Loxo Oncology showed us management is serious about developing new targeted cancer therapies and we can reasonably expect the company to buy more mid-sized companies developing new tumor blasters treatments.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$327.27 (0.51%) $1.65
Dermira, Inc. Stock Quote
Dermira, Inc.
DERM

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.